Charpin C, Garcia S, Bouvier C, Martini F, Lavaut M, Allasia C, Bonnier P, Andrac L
Department of Pathology, Faculté de Médecine, Centre Hospitalier Régional et Universitaire de Marseille, France.
J Clin Pathol. 1997 Jul;50(7):586-90. doi: 10.1136/jcp.50.7.586.
To determine the prognostic significance and clinical relevance of cathepsin D detected by immunocytochemical assays (ICAs) in breast carcinomas.
151 patients presenting with palpable or impalpable breast carcinomas and who had not received any kind of adjuvant chemotherapy or endocrine therapy who were operated from January 1986 to May 1987 were studied. ICAs of tumour specimens were performed in optimal technical conditions (frozen sections, automated immunoperoxidase technique (Ventana), and computer assisted analysis of digitised coloured microscopic images (SAMBA)) to determine cathepsin D immunocytochemical expression. Results of quantitative ICAs were correlated with overall and disease free survival over 8.4 years of follow up in axillary lymph node positive and negative patients.
Cathepsin D immunocytochemical expression in tumours of 15% or more was significantly associated with poor overall survival in the whole group and in node positive patients (Kaplan Meier, log rank test p = 0.003 and p = 0.007); however, it was not correlated with survival in node negative patients. Cathepsin D immunocytochemical expression (> 15%) correlated with short disease free (p = 0.015) and short recurrence free survival (p = 0.021) in the group as a whole but not when node positive and negative patients were evaluated separately.
In optimal conditions (automated and quantitative ICAs on frozen sections) cathepsin D immunohistochemical expression is a significant prognostic indicator in terms of overall, disease free, and recurrence free survival; however, there is no correlation when node negative patients are considered separately.
确定免疫细胞化学检测法(ICAs)检测的组织蛋白酶D在乳腺癌中的预后意义及临床相关性。
对1986年1月至1987年5月间接受手术的151例有可触及或不可触及乳腺癌且未接受任何辅助化疗或内分泌治疗的患者进行研究。在最佳技术条件下(冰冻切片、自动免疫过氧化物酶技术(Ventana)以及数字化彩色显微图像计算机辅助分析(SAMBA))对肿瘤标本进行ICAs检测,以确定组织蛋白酶D的免疫细胞化学表达。对腋窝淋巴结阳性和阴性患者进行8.4年随访,将定量ICAs结果与总生存率和无病生存率进行关联分析。
组织蛋白酶D免疫细胞化学表达在15%及以上的肿瘤患者中,与全组及淋巴结阳性患者的总生存率较差显著相关(Kaplan-Meier法,对数秩检验p = 0.003和p = 0.007);然而,与淋巴结阴性患者的生存率无关。组织蛋白酶D免疫细胞化学表达(> 15%)与全组患者的无病生存期短(p = 0.015)和无复发生存期短(p = 0.021)相关,但分别评估淋巴结阳性和阴性患者时则无相关性。
在最佳条件下(冰冻切片的自动定量ICAs),组织蛋白酶D免疫组化表达是总体、无病和无复发生存率方面的重要预后指标;然而,单独考虑淋巴结阴性患者时则无相关性。